RT Journal Article
SR Electronic
T1 Duration of viable virus shedding in SARS-CoV-2 omicron variant infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.01.22271582
DO 10.1101/2022.03.01.22271582
A1 Boucau, Julie
A1 Marino, Caitlin
A1 Regan, James
A1 Uddin, Rockib
A1 Choudhary, Manish C.
A1 Flynn, James P.
A1 Chen, Geoffrey
A1 Stuckwisch, Ashley M.
A1 Mathews, Josh
A1 Liew, May Y.
A1 Singh, Arshdeep
A1 Lipiner, Taryn
A1 Kittilson, Autumn
A1 Melberg, Meghan
A1 Li, Yijia
A1 Gilbert, Rebecca F.
A1 Reynolds, Zahra
A1 Iyer, Surabhi L.
A1 Chamberlin, Grace C.
A1 Vyas, Tammy D.
A1 Goldberg, Marcia B.
A1 Vyas, Jatin M.
A1 Li, Jonathan Z.
A1 Lemieux, Jacob E.
A1 Siedner, Mark J.
A1 Barczak, Amy K.
YR 2022
UL http://medrxiv.org/content/early/2022/03/02/2022.03.01.22271582.abstract
AB Clinical features of SARS-CoV-2 Omicron variant infection, including incubation period and transmission rates, distinguish this variant from preceding variants. However, whether the duration of shedding of viable virus differs between omicron and previous variants is not well understood. To characterize how variant and vaccination status impact shedding of viable virus, we serially sampled symptomatic outpatients newly diagnosed with COVID-19. Anterior nasal swabs were tested for viral load, sequencing, and viral culture. Time to PCR conversion was similar between individuals infected with the Delta and the Omicron variant. Time to culture conversion was also similar, with a median time to culture conversion of 6 days (interquartile range 4-8 days) in both groups. There were also no differences in time to PCR or culture conversion by vaccination status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Massachusetts Consortium for Pathogen Readiness (grants to J.Z.L, J.E.L, M.B.G., M.J.S, and A.K.B.) and the Massachusetts General Hospital Department of Medicine (grant to J.M.V.). The BSL3 laboratory where viral culture work was performed is supported by the Harvard CFAR (P30 AI060354).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mass General Brigham IRB gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.